Protego Biopharma, a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, announced the completion of an oversubscribed $130 million Series B financing. The round was led by Novartis Venture Fund and Forbion, with participation from new investors including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Existing investors, including Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research, also participated, underscoring their continued conviction in the Protego approach.